Skip to content
  • +44 808 189 5057 (toll free)
  • clientserviceseurope@guardanthealth.com

Conquering cancer with data

Through the power of blood tests, we can uncover clues that allow doctors to discover cancer early and find the best way to treat it.

Guardant Health leads the way in precision oncology testing.

Our proprietary, cutting-edge technology measures changes in circulating tumour DNA (ctDNA) to:

+ Get a highly sensitive, minimally invasive assessment
of cancer1

+ Detect spatial and temporal evolution of a tumour2

See what Guardant Health can do

The Guardant portfolio is
backed by data from:

> 1000000

patients tested

> 270

clinical outcomes studies

> 670

peer-reviewed publications & research abstracts

Our Approach

We’re dedicated to the belief that precision oncology has the extraordinary power to improve patient outcomes.

Explore our approach

Unlock the most dynamic view of cancer
with Guardant Health.

Identify Minimal Residual Disease clinical decision making in early-stage cancer setting.

Same time, saves time; initiate liquid before or at the same time as tissue.5,6

Conquering Cancer With Data

We are dedicated to helping patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock.

Guardant Health
is an established industry partner.

> 670

peer-reviewed publications

> 270

clinical outcomes studies

> 15 k

ordering oncologists

> 1000000

test results

References: 1. Guardant360® Liquid Assay Specifications. October 14, 2024. Guardant Health, Inc. Redwood City, CA., 2. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047., 3. Guardant Health data on file. October 19, 2023. Guardant Health, Inc. Redwood City, CA., 4. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410., 5. Cui W, Milner-Watts C, O’Sullivan H,
et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first-line advanced NSCLC patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012., 6. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA.